CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate.
Human T cells adopt a CD28-CD57+ phenotype in chronic viral infections and this has been hypothesized to result from continuous stimulation, however this phenotype may be due to direct viral effects on T cells. Employing MS patients before and after chronic in vivo administration of the antigen glatiramer acetate (GA) we examine this hypothesis. Pre-treatment glatiramer acetate-specific CD8 T cells were CD57-Perforin-. This changed to a predominantly CD28-CD57+Perforin+ response after administration of this drug. This phenotype was only observed after chronic stimulation and not in a recall response to mumps. The relevance to GA's mechanism of action is discussed.
Ratts
Robert B
RB
Department of Neurology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9036, USA.
Lovett-Racke
Amy E
AE
Choy
Judy
J
Northrop
Sara C
SC
Hussain
Rehana Z
RZ
Karandikar
Nitin J
NJ
Racke
Michael K
MK
D000328:Adult; D018106:CD28 Antigens / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018959:CD57 Antigens / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology*; D010455:Peptides / Q000627:therapeutic use*; D054353:Perforin; D052899:Pore Forming Cytotoxic Proteins; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology
D018106:CD28 Antigens; D018959:CD57 Antigens; D007166:Immunosuppressive Agents; D008562:Membrane Glycoproteins; D010455:Peptides; D052899:Pore Forming Cytotoxic Proteins; D054353:Perforin; D000068717:Glatiramer Acetate